SCHEMBL6093050

SCHEMBL6093050

CC(O)Oc1ccc(C2NC(=O)c3cccc4c3N2CCC4=O)cc1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TNKS2 Q9H2K2 3/20 0.34
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 3/20 0.33
NPSR1 Q6W5P4 1/20 0.33
GPR174 Q9BXC1 1/20 0.32
BRD4 O60885 1/20 0.32
CREBBP Q92793 1/20 0.32
TSHR P16473 1/20 0.32
GAA P10253 2/20 0.31
CYP2C19 P33261 1/20 0.31
USP2 O75604 1/20 0.31
HSD17B10 Q99714 1/20 0.31
POLB P06746 1/20 0.31
PKM P14618 1/20 0.31
ABCB1 P08183 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6090852 0.91 TSHR (0.40) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6090262 0.88 HTR2C (0.31) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6092226 0.85 TNKS2 (0.45) TNKS2KDM4EALDH1A1NPSR1GAA
SCHEMBL6089480 0.82 TNKS2 (0.42) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6093007 0.82 PARP1 (0.33) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6090465 0.82 PARP1 (0.33) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6093054 0.81 GPR174 (0.41) TNKS2KDM4EALDH1A1GPR174GAA
SCHEMBL6090523 0.80 TNKS2 (0.39) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6091873 0.79 MEN1 (0.42) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6089877 0.79 PARP1 (0.39) HTR2CHTR2BKDM4EALDH1A1GPR174

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004028-A1 Novel PARP inhibitor MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1582520-A1 NOVEL PARP INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004028-A1 Novel PARP inhibitor PARP1, PARP2, PARP11 TNKS2 15/4885HTR2C 3206/4885HTR2B 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.